Drug Innovation
Commentary
Drug company profits don’t threaten lives; price controls do
More than 4 in 5 Americans blame the pharmaceutical industry’s profits for the high prices of prescription drugs. It’s little wonder, then, that roughly the same share supports placing price controls on prescription drugs through Medicare. The logic is straight out of Robin Hood. Our leaders should take from the ...
Sally C. Pipes
April 23, 2025
Commentary
Deregulation Is The Pathway To Greater Pharmaceutical Innovation
Surveys confirm that most Americans recognize the value of prescription drugs. But the same surveys also show that Americans are worried that they will be unable to afford needed medicines. These conflicting feelings exemplify the inherent tension when it comes to prescription drugs – how do we incentivize innovation to ...
Wayne H Winegarden
April 21, 2025
Blog
Imposing Price Controls on U.S. Drugs Won’t Level the Playing Field
The cost of capital for developing a new drug is $2.9 billion, including post approval research and development costs. Meanwhile, the process to develop a drug takes 10 years and only 12 percent of drugs make it to market. These costs do not change simply because governments impose price controls ...
Wayne Winegarden
March 24, 2025
Drug Importation
Sally Pipes – The World’s Medicine Chest
This week, we present a special presentation of our recent webinar with Sally Pipes, PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy, discussing her new book, The World’s Medicine Chest: How America Achieved Pharmaceutical Supremacy – and How to Keep It (Encounter Books). The book explores ...
Pacific Research Institute
March 3, 2025
340B
Watch Webinar with Sally Pipes on her new book, “The World’s Medicine Chest”
Watch the webinar with Sally Pipes, PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy, discussing her new book, The World’s Medicine Chest: How America Achieved Pharmaceutical Supremacy – and How to Keep It (Encounter Books). The book explores how America became the world’s leader in biopharmaceutical ...
Pacific Research Institute
February 26, 2025
Drug Innovation
Why Failure-to-Market Claims Are Preempted Under Federal Law
A California appellate court invented out of whole cloth a new and troubling theory of tort liability. Specifically, the court held that drug companies have a duty to develop and bring to market drugs that are supposedly safer and more effective than another, FDA-approved drug the company sells already. The ...
Richard A. Epstein and Benjamin Flowers
February 5, 2025
Book
Read the new book from Sally Pipes “The World’s Medicine Chest”
Just released from PRI – read The World’s Medicine Chest, the latest book from PRI President, CEO and Thomas W. Smith Fellow in Health Care Policy. <The World’s Medicine Chest explores how America became the world’s leader in biopharmaceutical innovation through market capitalism. Click here to register to watch a special ...
Sally C. Pipes
February 4, 2025
Blog
Read about a last minute Biden administration plan the Trump administration should undo
CMS’ Drug Price Controls Have Expanded to the Next 15 Medicare Part D Drugs
For every complex problem there is an answer that is clear, simple, and wrong. H.L. Mencken Back in 2022, the Biden Administration reasoned that drug costs are too high and devised a clear and simple answer: incorporate a Maximum Fair Price (MFP) provision into the Inflation Reduction Act of 2022 ...
Wayne Winegarden
January 20, 2025
Drug Innovation
PRI Responds to CMS Adding 15 Additional Drugs That Will Be Subjected to Government Price Controls
PRI’s scholars responded to today’s action by the Centers for Medicare & Medicaid (CMS) announcing 15 additional drugs under Medicare Part D that will be subject to government price setting effective January 1, 2027. The action was authorized by the Inflation Reduction Act signed by President Biden in August 2022. ...
Sally Pipes and Wayne Winegarden
January 17, 2025
Biosimilars
The Biosimilar Promise
Despite Achievements, Barriers That Discourage Biosimilar Use Remain
Despite Achievements, Barriers That Discourage Biosimilar Use Remain By Wayne Winegarden | December 2, 2024 READ PDF Executive Summary The Inflation Reduction Act’s price controls discourage biosimilar development. Payment system inefficiencies, such as the buy-and-bill payment system and rebate walls, disincentivize the use of lower cost biosimilars. Despite the savings ...
Wayne Winegarden
December 2, 2024
Drug company profits don’t threaten lives; price controls do
More than 4 in 5 Americans blame the pharmaceutical industry’s profits for the high prices of prescription drugs. It’s little wonder, then, that roughly the same share supports placing price controls on prescription drugs through Medicare. The logic is straight out of Robin Hood. Our leaders should take from the ...
Deregulation Is The Pathway To Greater Pharmaceutical Innovation
Surveys confirm that most Americans recognize the value of prescription drugs. But the same surveys also show that Americans are worried that they will be unable to afford needed medicines. These conflicting feelings exemplify the inherent tension when it comes to prescription drugs – how do we incentivize innovation to ...
Imposing Price Controls on U.S. Drugs Won’t Level the Playing Field
The cost of capital for developing a new drug is $2.9 billion, including post approval research and development costs. Meanwhile, the process to develop a drug takes 10 years and only 12 percent of drugs make it to market. These costs do not change simply because governments impose price controls ...
Sally Pipes – The World’s Medicine Chest
This week, we present a special presentation of our recent webinar with Sally Pipes, PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy, discussing her new book, The World’s Medicine Chest: How America Achieved Pharmaceutical Supremacy – and How to Keep It (Encounter Books). The book explores ...
Watch Webinar with Sally Pipes on her new book, “The World’s Medicine Chest”
Watch the webinar with Sally Pipes, PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy, discussing her new book, The World’s Medicine Chest: How America Achieved Pharmaceutical Supremacy – and How to Keep It (Encounter Books). The book explores how America became the world’s leader in biopharmaceutical ...
Why Failure-to-Market Claims Are Preempted Under Federal Law
A California appellate court invented out of whole cloth a new and troubling theory of tort liability. Specifically, the court held that drug companies have a duty to develop and bring to market drugs that are supposedly safer and more effective than another, FDA-approved drug the company sells already. The ...
Read the new book from Sally Pipes “The World’s Medicine Chest”
Just released from PRI – read The World’s Medicine Chest, the latest book from PRI President, CEO and Thomas W. Smith Fellow in Health Care Policy. <The World’s Medicine Chest explores how America became the world’s leader in biopharmaceutical innovation through market capitalism. Click here to register to watch a special ...
Read about a last minute Biden administration plan the Trump administration should undo
CMS’ Drug Price Controls Have Expanded to the Next 15 Medicare Part D Drugs
For every complex problem there is an answer that is clear, simple, and wrong. H.L. Mencken Back in 2022, the Biden Administration reasoned that drug costs are too high and devised a clear and simple answer: incorporate a Maximum Fair Price (MFP) provision into the Inflation Reduction Act of 2022 ...
PRI Responds to CMS Adding 15 Additional Drugs That Will Be Subjected to Government Price Controls
PRI’s scholars responded to today’s action by the Centers for Medicare & Medicaid (CMS) announcing 15 additional drugs under Medicare Part D that will be subject to government price setting effective January 1, 2027. The action was authorized by the Inflation Reduction Act signed by President Biden in August 2022. ...
The Biosimilar Promise
Despite Achievements, Barriers That Discourage Biosimilar Use Remain
Despite Achievements, Barriers That Discourage Biosimilar Use Remain By Wayne Winegarden | December 2, 2024 READ PDF Executive Summary The Inflation Reduction Act’s price controls discourage biosimilar development. Payment system inefficiencies, such as the buy-and-bill payment system and rebate walls, disincentivize the use of lower cost biosimilars. Despite the savings ...